SCHEMBL30028371

SCHEMBL30028371

N=C(N)NCCC[C@H](NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 7/20 0.53
▸ UTS2R Q9UKP6 1/20 0.48
▸ C5AR1 P21730 1/20 0.46
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46
▸ TUBB6 Q9BUF5 1/20 0.46
▸ TUBB2B Q9BVA1 1/20 0.46
▸ TUBB1 Q9H4B7 1/20 0.46
▸ OPRM1 P35372 3/20 0.45
▸ OPRD1 P41143 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31555127 0.96 MC4R (0.53) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL31555115 0.96 MC4R (0.53) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL31555128 0.96 MC4R (0.53) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL31555130 0.96 MC4R (0.53) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL29534236 0.96 MC4R (0.55) MC4RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL31555131 0.95 MC4R (0.56) MC4RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL31555134 0.95 MC4R (0.56) MC4RC5AR1TUBB4ATUBBTUBA3C
SCHEMBL30510396 0.94 MC4R (0.50) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL31555121 0.94 MC4R (0.54) MC4RUTS2RC5AR1TUBB4ATUBB
SCHEMBL31555124 0.94 MC4R (0.54) MC4RUTS2RC5AR1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182519-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA S.A.S. (FR) 2024-06-06 — — US disclosed
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA SAS (FR) 2022-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182519-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN MC4R, MC3R, MC1R MC4R 1/4885UTS2R 158/4885C5AR1 563/4885
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY MC4R, MC1R, MC3R MC4R 1/4885UTS2R 255/4885C5AR1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback